Lutetium-177 also powers the therapeutic Lutathera-which Novartis recently pitched as a potential first-line therapy in gastroenteropancreatic neuroendocrine tumors, also known as GEP-NETs, following a successful phase 3 trial last month that combined it with the synthetic hormone Sandostatin.ĪAA has also received diagnostic approvals for Netspot and SomaKit, which use gallium-68 to label neuroendocrine tumors Locametz, which employs the same radioisotope in prostate cancer and Gluscan, which helps track glucose metabolism with fluoride-18. Novartis’ AAA division also markets and develops anti-cancer therapies using the same molecular binders-by swapping out a weaker radioactive isotope for a stronger one, it aims to turn precision diagnostic imaging agents into tumor-cell-killing drugs.įor example, the company’s pipeline lists two products in early development targeting a protein found on the surface of cells that help feed blood to growing glioblastoma brain tumors: one employing a gamma-ray-emitting isotope of gallium, used in diagnostic PET/CT scans, while the other taps lutetium-177, which emits damaging beta particles. From financial assistance to online support, learn how we can make it as simple as possible for you to get connected to resources that can help. Thats why we go beyond the medicines we make to bring you the support and resources you need to help you during your journey. Lilly to surf radiopharmaceutical wave with $1.4B acquisition of Point Biopharma At Novartis Oncology, patients are our priority.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |